Researchers discover unexpected role of an immune system receptor; blocking it halts human cancer cell growth and improves survival in animal models
For some cancers, initial treatment with chemotherapy brings positive, but only temporary, results: tumors shrink, but then rebound as the cancer becomes drug-resistant. This pattern of remission-resistance-relapse is particularly true for pancreatic cancer, an aggressive disease in which early success is often countered by eventual disease progression.
To wit: The one-year relative survival rate for pancreatic cancer is 20 percent, according to the American Cancer Society. The five-year rate is just 7 percent.
The reason: Current multidrug chemotherapy regimens targeting pancreatic cancer typically do not fully eradicate all cancer cells, leaving behind drug-resistant cells that harbor aberrant stem cell properties and can drive tumor regrowth and metastasis.
In a new paper publishing in the April 4, 2019 online issue of Cell, an international team of scientists led by researchers at University of California San Diego School of Medicine employed an array of next-generation sequencing and gene-editing tools, such as CRISPR, to map the molecular dependencies —and thus vulnerabilities — of pancreatic cancer stem cells.
Most notably, they found that a key hormone receptor called retinoic acid receptor-related orphan receptor gamma or ROR?, previously studied in inflammation and T-cell differentiation, was especially active during pancreatic cancer progression, and that blocking it markedly slowed patient derived tumor growth and improved survival in animal models.
“These studies revealed an unexpected role for immuno-regulatory genes in the maintenance of the most aggressive, drug-resistant cells in pancreatic cancer,” said senior study author Tannishtha Reya, PhD, UC San Diego professor in the departments of Pharmacology and Medicine. In particular, ROR? emerged as a key regulator. ROR? rose with cancer progression and its inhibition through genetic and pharmacological approaches resulted in a striking defect in pancreatic cancer growth.
“Our work shows that immune system signals are hijacked by pancreatic cancer, and suggests that therapies currently being tested for autoimmune indications should be considered for testing in pancreatic cancer,” said Reya.
Using genome scale approaches to map stem cell dependencies in pancreatic cancer “will be invaluable for understanding the basis of therapy resistance and recurrence and for discovering new vulnerabilities in pancreatic cancer,” said Reya. “Beyond providing new scientific insight, this work can help identify pathways for which clinical grade inhibitors may already exist and can thus be rapidly tested in pancreatic cancer.”
In particular, she said the discovery of ROR?‘s role in promoting tumor growth provides a new avenue for research and potential therapies. “One exciting aspect is the possibility that nuclear hormone receptors could represent therapeutic targets for pancreatic cancer. In fact, drugs targeting ROR? have already been developed by several pharmaceutical companies, and are in trials for autoimmune diseases. Our findings suggest that these agents could also be a valuable therapeutic strategy for pancreatic cancer.”
The Latest on: Pancreatic cancer
via Google News
The Latest on: Pancreatic cancer
- PharmaCyte Biotech to Change Future of Treating Diseases with Validation of Encapsulation Technology in Pancreatic Cancer Trialon October 28, 2019 at 5:41 pm
The company is closer than ever to its upcoming Phase 2b clinical trial in locally advanced, inoperable pancreatic cancer (LAPC) that could give patients a new lease on life by shrinking their tumors ...
- PR55α regulatory subunit of PP2A inhibits the MOB1/LATS cascade and activates YAP in pancreatic cancer cellson October 28, 2019 at 11:32 am
We have previously reported an essential role of PR55α, a PP2A regulatory subunit, in the support of oncogenic phenotypes, including in vivo tumorigenicity/metastasis of pancreatic cancer cells. In ...
- Global Rise in Pancreatic Cancer Deathson October 28, 2019 at 7:35 am
BARCELONA, Spain — The global burden of pancreatic cancer has risen sharply since 1990, with the incidence increasing and death rates more than doubling to 2017, reports a new study that forms part of ...
- Can Fungi In The Gut Cause Pancreatic Cancer?on October 24, 2019 at 6:13 pm
Only 9.3 percent of people diagnosed with pancreatic cancer made it past the remission period between 2009 and 2015, according to the National Cancer Institute (NCI). Researchers at New York ...
- Scientists discover new survival strategy for oxygen-starved pancreatic cancer cellson October 24, 2019 at 6:16 am
When fast-growing tumor cells run out of oxygen, they quickly sprout new blood vessels to keep growing, a process called angiogenesis. By blocking pancreatic cancer's oxygen-sensing machinery—the same ...
- Obesity may be upping rates of pancreatic cancer worldwideon October 23, 2019 at 2:16 pm
Rising rates of obesity and diabetes could be pushing up rates of pancreatic cancer across the globe, a new report suggests. Global rates of colon cancer are also on the rise, although fewer cases are ...
- Quiet Riot’s Frankie Banali reveals stage four pancreatic cancer diagnosison October 22, 2019 at 5:08 pm
The post Quiet Riot’s Frankie Banali reveals stage four pancreatic cancer diagnosis appeared first on Consequence of Sound. Frankie Banali, legendary drummer for Quiet Riot, has been diagnosed with ...
- A novel KDM5A/MPC-1 signaling pathway promotes pancreatic cancer progression via redirecting mitochondrial pyruvate metabolismon October 22, 2019 at 5:28 am
TCGA database, paired PDA and adjacent normal pancreatic tissues, PDA tissue array and cell lines were used to determine ... SurvExpress: an online biomarker validation tool and database for cancer ...
- Colorectal and pancreatic cancer rates up 10% in last 30 years, major study revealson October 22, 2019 at 5:05 am
The results of a major study across 195 countries, presented today at UEG Week Barcelona 2019, indicate that global death rates for pancreatic cancer and incidence rates for colorectal cancer both ...
- Peptide-based nanoparticles can suppress pancreatic cancer growth without adverse effectson October 21, 2019 at 12:09 pm
Despite advances in cancer survival, more than 90 percent of people with pancreatic cancer die within five years. Most patients with pancreatic tumors (and half of those with colorectal cancers) carry ...
via Bing News